Innovative Multispecific Nanobody Therapeutic Targeting ALB and EGFR for Cancer

VHH-P582 is a humanized, multispecific nanobody designed to target albumin (ALB) and epidermal growth factor receptor (EGFR) for the potential treatment of cancer. Currently in the Biological Testing stage of development, this engineered construct integrates multiple single domain antigen-binding domains within a prodrug antibody format. By leveraging the biological roles of ALB and EGFR, VHH-P582 aims to enhance therapeutic selectivity and engage key immunological pathways relevant to cancer pathophysiology. This next-generation nanobody holds significant promise as a novel cancer therapeutic, addressing current limitations in targeting tumor microenvironments and achieving deeper tissue penetration.

Licensing Opportunity

VHH-P582 is open for partnering and out-licensing opportunities. We invite potential collaborators and industry partners to explore co-development and commercialization for this innovative cancer therapeutic.

Development Phase

Modality

VHH-P582 utilizes a sophisticated, multispecific construct that combines single domain antigen-binding domains (nanobodies) for precise recognition of EGFR and ALB, along with constrained single-chain variable fragments for CD3 and CD28 engagement. The sequence includes non-cleavable and matrix metalloproteinase-9-sensitive linkers, enabling prodrug activation within the tumor microenvironment. Nanobody modalities offer favorable pharmacokinetics due to their compact molecular weight, high solubility, and superior tissue permeability. For cancer therapy, these features facilitate deeper tumor penetration, greater stability, and the potential for multi-functional activity in complex biological settings, setting a strong foundation for the clinical utility of VHH-P582.

Target

ALB and EGFR serve as central targets in the VHH-P582 program. ALB, a soluble plasma protein, plays a key role in maintaining oncotic pressure and drug transport within the body. EGFR, a receptor tyrosine kinase, is predominantly expressed on epithelial cells and is frequently overexpressed in diverse cancer types. Targeting EGFR is a well-established strategy in oncology, as its aberrant activation promotes tumor growth, progression, and survival. ALB is widely present in circulation, enabling enhanced pharmacokinetics and potential tumor selectivity when used as a drug carrier. By simultaneously engaging ALB and EGFR, VHH-P582 enhances circulating half-life, targets tumor cells directly, and represents a powerful, dual-pronged approach for cancer therapy.

Mechanism of Action

VHH-P582 acts by binding to ALB and EGFR through its engineered nanobody domains, facilitating stable plasma retention and selective tumor cell targeting. The construct harnesses T cell engagement by including anti-CD3 and anti-CD28 single-chain variable fragments, promoting immune synapse formation and T cell activation specifically in the tumor microenvironment. Incorporation of a conditionally activated prodrug design, utilizing matrix metalloproteinase-9-cleavable linkers, restricts T cell-mediated cytotoxicity primarily to tumor sites, minimizing off-target effects. The nanobody-based platform enables versatile therapeutic formats, offering expansion potential toward antibody-drug conjugates, bispecifics, or other multifunctional therapeutics.

Cancer

Cancer encompasses a heterogeneous group of diseases characterized by uncontrolled cell proliferation and the capacity for local invasion and metastasis. Globally, cancer represents one of the leading causes of morbidity and mortality, with millions of new cases diagnosed each year. Standard treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and molecularly targeted agents. While advancements have improved outcomes for some cancer types, significant challenges remain, including drug resistance, relapse, toxicities, and limited efficacy in advanced-stage disease. There is a profound need for therapeutics that can more precisely target tumor cells while sparing normal tissue and minimizing adverse effects. VHH-P582, designed for multi-targeting and immunomodulation, addresses these gaps by potentially achieving deeper tumor penetration, targeted immune engagement, and improved safety for cancer patients.